In the light of therapeutic strategies modulating IL-22 bioactivity in IBD that are currently under evaluation, we thus sought to extend further the characterization of IL-22BP production and distribution in intestinal tissues from a cohort of CD patients. Here, IL22RA2 is linked to inflammatory bowel disease.